

## **Supplement**

### **Preserved T-cell Response in anti-CD20 treated Multiple Sclerosis Patients following SARS-CoV-2 Vaccination**

Simon Faissner<sup>1</sup>, Neele Heitmann<sup>1</sup>, Ricarda Rohling<sup>1</sup>, Ulas Ceylan<sup>1</sup>, Marielena Bongert<sup>1</sup>,  
Corinna Marheinecke<sup>2</sup>, Xiomara Pedreiturria<sup>1</sup>, Ilya Ayzenberg<sup>1</sup>, Kerstin Hellwig<sup>1</sup>, Ingo  
Schmitz<sup>3</sup>, Stephanie Pfaender<sup>2</sup>, Ralf Gold<sup>1</sup>


<sup>1</sup> Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany,

<sup>2</sup> Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum,  
Germany


<sup>3</sup> Department of Molecular Immunology, Ruhr-University Bochum, Bochum, Germany

**Supplementary Table 1: Antibodies used for flow cytometry.**


	<b>antibody</b>	<b>conjugate/dye</b>	<b>dilution</b>
<b>Viability</b>		Zombie Aqua™	1/1,500
<b>Extracellular staining</b>	anti-CD3	BV785	1/200
	anti-CD4	FITC	1/200
	anti-CD8a	APC/Fire750	1/200
<b>Intracellular staining</b>	anti-IL-2	APC	1/50
	anti-IL-4	PE	1/50
	anti-IFN- $\gamma$	PerCP-Cy5.5	1/50




**Supplementary Figure 1: Gating strategy of T cell subpopulations in SARS-CoV-2 peptide stimulated PBMCs after flow cytometry measurements.** The gating strategy was applied to data shown in Figures 3-5. a) CD8<sup>+</sup> and CD4<sup>+</sup> T cells were gated within viable single T cells. b) Subpopulations of CD4<sup>+</sup> T helper cells. c) Identification of subpopulations of CD8<sup>+</sup> cytotoxic T cells.




**Supplementary Figure 2: Correlation of Anti-SARS-CoV-2-Spike titer and T cell populations in HC and aCD20 treated MS patients.** No correlation of anti-SARS-CoV-2-Spike titers and a) CD3<sup>+</sup> T cell frequencies, b) CD4<sup>+</sup> Th helper cell frequencies and c) CD8<sup>+</sup> cytotoxic T cell frequencies. Reference range of Anti-SARS-CoV2 antibodies: <0,8-2500 U/mL. Data were analyzed with non-parametric, two-tailed Spearman correlation.




**Supplementary Figure 3: Correlation of neutralization capacity and frequencies of CD3<sup>+</sup>, CD4<sup>+</sup> and CD8<sup>+</sup> T cell populations.** Correlation of WT neutralization with frequencies of a) CD3<sup>+</sup>, c) CD4<sup>+</sup> and e) CD8<sup>+</sup> T cells and correlation of delta neutralization with frequencies of b) CD3<sup>+</sup>, d) CD4<sup>+</sup> and f) CD8<sup>+</sup> T cells. Data were analyzed with non-parametric, two-tailed Spearman correlation.



**Supplementary Figure 4: Correlation of age with CD3<sup>+</sup> T cell population.** Negative correlation of age with CD3<sup>+</sup> T cell populations in aCD20 treated MS patients. Data were analyzed with non-parametric, two-tailed Spearman correlation.



**Supplementary Figure 5: Correlation of anti-SARS-CoV-2-Spike titer and CD4<sup>+</sup> Thelper cell subpopulations.** Anti-SARS-CoV-2-Spike titers did not correlate with frequencies of a) CD4<sup>+</sup>IFN- $\gamma$ <sup>+</sup> cells, b) CD4<sup>+</sup>IL-2<sup>+</sup> cells, c) CD4<sup>+</sup>IFN- $\gamma$ <sup>+</sup>IL-2<sup>+</sup> cells or d) CD4<sup>+</sup>IL-4<sup>+</sup> cells. Reference range of anti-SARS-CoV-2 antibodies: <0,8-2500 U/mL. Data were analyzed with non-parametric, two-tailed Spearman correlation.



**Supplementary Figure 6: Correlation of anti-SARS-CoV-2-Spike titer and CD8<sup>+</sup> Tc cell subpopulations.** Anti-SARS-CoV-2-Spike titers correlated with frequencies of a) CD8<sup>+</sup>IFN- $\gamma$ <sup>+</sup> cells in aCD20 treated MS patients but not in HC. No correlation of anti-SARS-CoV-2-Spike titers with b) CD8<sup>+</sup>IL-2<sup>+</sup> cells or c) CD8<sup>+</sup>IFN- $\gamma$ <sup>+</sup>IL-2<sup>+</sup> cells. Reference range of anti-SARS-CoV-2 antibodies: <0,8-2500 U/mL. Data were analyzed with non-parametric, two-tailed Spearman correlation.